Covered recipient · General Payments record
JOHN RUBINO
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$1,823.22
39 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,012.33 | 4 |
| Food and Beverage | $810.89 | 35 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $1,342.25 | 5 |
| Amgen Inc. | $82.90 | 6 |
| Janssen Pharmaceuticals, Inc | $49.57 | 4 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $47.89 | 3 |
| Amarin Pharma Inc. | $46.37 | 3 |
| Merck Sharp & Dohme Corporation | $32.85 | 3 |
| Gilead Sciences, Inc. | $29.79 | 2 |
| AstraZeneca Pharmaceuticals LP | $25.33 | 2 |
| Astellas Pharma US Inc | $20.71 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.33 | 1 |
| Novartis Pharmaceuticals Corporation | $17.34 | 1 |
| Radius Health, Inc. | $17.20 | 1 |
| Daiichi Sankyo Inc. | $16.60 | 1 |
| AbbVie, Inc. | $15.58 | 1 |
| Novo Nordisk Inc | $12.96 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $12.75 | 1 |
| GlaxoSmithKline, LLC. | $11.01 | 1 |
| Lilly USA, LLC | $10.95 | 1 |
| Kowa Pharmaceuticals America, Inc. | $10.84 | 1 |
Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOHN RUBINO
NPI 1962543280 · CMS profile ID 43312
Allopathic & Osteopathic Physicians / Internal Medicine
RALEIGH, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1962543280?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOHN RUBINO, NPI 1962543280, CMS profile ID 43312. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962543280?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). JOHN RUBINO, NPI 1962543280, CMS profile ID 43312. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962543280?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- JOHN RUBINO, NPI 1962543280, CMS profile ID 43312, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1962543280?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
39 matching records · $1,823.22 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–39 of 39.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $11.84 | 12/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659250837 | CMS |
| Amarin Pharma Inc. | $12.39 | 12/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699282451 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $12.75 | 11/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681998927 | CMS |
| Merck Sharp & Dohme Corporation | $10.74 | 11/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695868903 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.01 | 11/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685718589 | CMS |
| AbbVie, Inc. | $15.58 | 10/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648088187 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.59 | 10/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700276625 | CMS |
| Novo Nordisk Inc | $12.96 | 10/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 674975467 | CMS |
| Amgen Inc. | $17.12 | 10/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662547099 | CMS |
| Astellas Pharma US Inc | $20.71 | 10/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655746611 | CMS |
| Janssen Pharmaceuticals, Inc | $12.58 | 09/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659250829 | CMS |
| Gilead Sciences, Inc. | $12.28 | 09/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681595261 | CMS |
| GlaxoSmithKline, LLC. | $11.01 | 08/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671434051 | CMS |
| Amarin Pharma Inc. | $16.22 | 08/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699203747 | CMS |
| Lilly USA, LLC | $10.95 | 08/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657914525 | CMS |
| Amgen Inc. | $13.43 | 07/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662547122 | CMS |
| Radius Health, Inc. | $17.20 | 07/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 683933285 | CMS |
| Daiichi Sankyo Inc. | $16.60 | 07/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695326079 | CMS |
| Gilead Sciences, Inc. | $17.51 | 06/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681595259 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $13.34 | 06/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700276627 | CMS |
| Amarin Pharma Inc. | $17.76 | 05/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699150335 | CMS |
| Amgen Inc. | $12.36 | 05/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662547119 | CMS |
| Janssen Pharmaceuticals, Inc | $13.93 | 04/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659250819 | CMS |
| PFIZER INC. | $47.13 | 04/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673769553 | CMS |
| Merck Sharp & Dohme Corporation | $9.31 | 04/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695400809 | CMS |
| Amgen Inc. | $13.13 | 03/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662547115 | CMS |
| PFIZER INC. | $264.05 | 03/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673245891 | CMS |
| PFIZER INC. | $224.87 | 03/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673246889 | CMS |
| PFIZER INC. | $476.28 | 03/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673246891 | CMS |
| PFIZER INC. | $329.92 | 03/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673247255 | CMS |
| AstraZeneca Pharmaceuticals LP | $11.32 | 03/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685750651 | CMS |
| Amgen Inc. | $13.51 | 03/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662547111 | CMS |
| Kowa Pharmaceuticals America, Inc. | $10.84 | 02/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 630297057 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.33 | 02/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684914617 | CMS |
| Novartis Pharmaceuticals Corporation | $17.34 | 02/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659852577 | CMS |
| Merck Sharp & Dohme Corporation | $12.80 | 01/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695918117 | CMS |
| Amgen Inc. | $13.35 | 01/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662547107 | CMS |
| Janssen Pharmaceuticals, Inc | $11.22 | 01/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659250815 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.96 | 01/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700276629 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,783,192.12 | 359 |
| PY2024 | Recipient | $66,231.01 | 15 |
| PY2024 | Principal investigator | $2,510,578.54 | 317 |
| PY2023 | Recipient | $6,417.61 | 4 |
| PY2023 | Principal investigator | $2,159,960.11 | 267 |
| PY2022 | Principal investigator | $2,441,546.83 | 286 |
| PY2021 | Principal investigator | $1,166,336.49 | 169 |
| PY2020 | Principal investigator | $1,326,147.90 | 192 |
| PY2019 | Principal investigator | $636,986.48 | 193 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
193 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Allergan Inc. | $591.50 | 12/31/2019 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 670123281 |
| Principal investigator 1 | Allergan Inc. | $14,306.59 | 12/31/2019 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670127509 |
| Principal investigator 1 | PFIZER INC. | $4,950.46 | 12/24/2019 | Non-covered Recipient Entity PMG Research of Raleigh LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671675911 |
| Principal investigator 1 | Allergan Inc. | $780.00 | 12/19/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670117331 |
| Principal investigator 1 | Novo Nordisk AS | $5,721.98 | 12/19/2019 | Non-covered Recipient Entity PMG RESEARCH INC | NN9536-4375 | No dispute reported | 06/30/2026 | 692453785 |
| Principal investigator 1 | Allergan Inc. | $17,073.40 | 12/16/2019 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670112395 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $1,521.00 | 12/16/2019 | Non-covered Recipient Entity PMG RESEARCH INC | K-877-302 | No dispute reported | 06/30/2026 | 629130057 |
| Principal investigator 1 | Allergan Inc. | $738.15 | 12/13/2019 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 670109721 |
| Principal investigator 1 | PFIZER INC. | $12,221.49 | 12/05/2019 | Non-covered Recipient Entity PMG Research of Raleigh LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671673531 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,000.00 | 12/05/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 685013973 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,500.00 | 12/05/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 685013989 |
| Principal investigator 1 | PFIZER INC. | $1,256.84 | 12/04/2019 | Non-covered Recipient Entity PMG Research of Raleigh | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 671670945 |
| Principal investigator 1 | Ferring International Pharmascience Center US | $665.00 | 12/03/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults | No dispute reported | 06/30/2026 | 655228547 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $6,433.20 | 12/03/2019 | Non-covered Recipient Entity PMG RESEARCH INC | K-877-302 | No dispute reported | 06/30/2026 | 629130059 |
| Principal investigator 1 | Novo Nordisk AS | $6,727.72 | 12/03/2019 | Non-covered Recipient Entity PMG RESEARCH INC | NN9536-4375 | No dispute reported | 06/30/2026 | 692453783 |
| Principal investigator 1 | PFIZER INC. | $628.42 | 11/23/2019 | Non-covered Recipient Entity PMG Research of Raleigh | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 671673591 |
| Principal investigator 1 | PFIZER INC. | $9,176.29 | 11/23/2019 | Non-covered Recipient Entity PMG Research of Raleigh LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671678369 |
| Principal investigator 1 | Novo Nordisk AS | $287.16 | 11/22/2019 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4375 | No dispute reported | 06/30/2026 | 706704063 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $500.00 | 11/20/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A Phase 3b Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Adult Participants with Recent Onset Chronic Cough | No dispute reported | 06/30/2026 | 691501129 |
| Principal investigator 1 | PFIZER INC. | $1,737.78 | 11/20/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671675025 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2,950.00 | 11/18/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691501747 |
| Principal investigator 1 | PFIZER INC. | $17.56 | 11/18/2019 | Non-covered Recipient Entity PMG Research of Raleigh | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 671684557 |
| Principal investigator 1 | PFIZER INC. | $145.50 | 11/18/2019 | Non-covered Recipient Entity PMG Research of Raleigh | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 671684627 |
| Principal investigator 1 | Allergan Inc. | $738.15 | 11/14/2019 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 670097919 |
| Principal investigator 1 | Allergan Inc. | $13,155.60 | 11/14/2019 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670098213 |
| Principal investigator 1 | PFIZER INC. | $628.42 | 11/13/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671670045 |
| Principal investigator 1 | Novo Nordisk AS | $50.00 | 11/12/2019 | Non-covered Recipient Entity PMG RESEARCH INC | NN9536-4375 | No dispute reported | 06/30/2026 | 692453773 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,056.00 | 11/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691476653 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $110.00 | 11/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691476967 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $13.20 | 11/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691476971 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $134.40 | 11/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691476973 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2.80 | 11/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691476977 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $15.20 | 11/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691538873 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $27.20 | 11/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691539521 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $38.00 | 11/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691539523 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $4.00 | 11/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691539691 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $484.00 | 11/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691539693 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $49.50 | 11/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691539695 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $5.20 | 11/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691541323 |
| Principal investigator 1 | PFIZER INC. | $50.00 | 11/06/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671669197 |
| Principal investigator 1 | PFIZER INC. | $65.00 | 11/06/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671673711 |
| Principal investigator 1 | PFIZER INC. | $375.00 | 11/06/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671675749 |
| Principal investigator 1 | PFIZER INC. | $2.69 | 11/04/2019 | Non-covered Recipient Entity PMG Research of Raleigh | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 671684629 |
| Principal investigator 1 | PFIZER INC. | $3,952.50 | 11/02/2019 | Non-covered Recipient Entity PMG Research of Raleigh LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671679079 |
| Principal investigator 1 | Allergan Inc. | $666.24 | 10/31/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670093045 |
| Principal investigator 1 | PFIZER INC. | $17.56 | 10/30/2019 | Non-covered Recipient Entity PMG Research of Raleigh | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 671684589 |
| Principal investigator 1 | PFIZER INC. | $5.38 | 10/30/2019 | Non-covered Recipient Entity PMG Research of Raleigh | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 671684591 |
| Principal investigator 1 | PFIZER INC. | $97.00 | 10/30/2019 | Non-covered Recipient Entity PMG Research of Raleigh | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 671684593 |
| Principal investigator 1 | Novo Nordisk AS | $7,992.80 | 10/29/2019 | Non-covered Recipient Entity PMG RESEARCH INC | NN9536-4375 | No dispute reported | 06/30/2026 | 692453771 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $2,305.80 | 10/25/2019 | Non-covered Recipient Entity PMG RESEARCH INC | K-877-302 | No dispute reported | 06/30/2026 | 629130055 |
| Principal investigator 1 | Allergan Inc. | $10,411.05 | 10/23/2019 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670090368 |
| Principal investigator 1 | PFIZER INC. | $9,676.51 | 10/23/2019 | Non-covered Recipient Entity PMG Research of Raleigh LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671669673 |
| Principal investigator 1 | PFIZER INC. | $11,311.56 | 10/23/2019 | Non-covered Recipient Entity PMG Research of Raleigh | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 671670943 |
| Principal investigator 1 | Allergan Inc. | $872.10 | 10/17/2019 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 670086795 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,176.00 | 10/11/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691429933 |
| Principal investigator 1 | PFIZER INC. | $4,001.38 | 10/09/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671668961 |
| Principal investigator 1 | PFIZER INC. | $6,242.59 | 10/04/2019 | Non-covered Recipient Entity PMG Research of Raleigh LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671672517 |
| Principal investigator 1 | PFIZER INC. | $1,885.26 | 10/04/2019 | Non-covered Recipient Entity PMG Research of Raleigh | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 671678029 |
| Principal investigator 1 | Ferring International Pharmascience Center US | $1,031.70 | 10/02/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults | No dispute reported | 06/30/2026 | 655228261 |
| Principal investigator 1 | PFIZER INC. | $1,372.27 | 10/02/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671670291 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $8,316.90 | 10/01/2019 | Non-covered Recipient Entity PMG RESEARCH INC | K-877-302 | No dispute reported | 06/30/2026 | 629130051 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $740.76 | 09/27/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691430915 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $741.95 | 09/27/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691451471 |
| Principal investigator 1 | Novo Nordisk AS | $7,625.86 | 09/26/2019 | Non-covered Recipient Entity PMG RESEARCH INC | NN9536-4375 | No dispute reported | 06/30/2026 | 692453781 |
| Principal investigator 1 | Allergan Inc. | $9,805.90 | 09/20/2019 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670078671 |
| Principal investigator 1 | Allergan Inc. | $2,236.30 | 09/20/2019 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 670078967 |
| Principal investigator 1 | PFIZER INC. | $12,289.55 | 09/20/2019 | Non-covered Recipient Entity PMG Research of Raleigh LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671676179 |
| Principal investigator 1 | PFIZER INC. | $3,603.82 | 09/11/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671669239 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,475.00 | 09/09/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691449653 |
| Principal investigator 1 | Novo Nordisk AS | $6,861.24 | 09/05/2019 | Non-covered Recipient Entity PMG RESEARCH INC | NN9536-4375 | No dispute reported | 06/30/2026 | 692453779 |
| Principal investigator 1 | PFIZER INC. | $2,356.59 | 08/28/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671672927 |
| Principal investigator 1 | PFIZER INC. | $13,068.70 | 08/28/2019 | Non-covered Recipient Entity PMG Research of Raleigh LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671678325 |
| Principal investigator 1 | Ferring International Pharmascience Center US | $6,680.40 | 08/26/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults | No dispute reported | 06/30/2026 | 655228035 |
| Principal investigator 1 | Ferring International Pharmascience Center US | $3,406.70 | 08/23/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults | No dispute reported | 06/30/2026 | 655227953 |
| Principal investigator 1 | PFIZER INC. | $1,942.99 | 08/20/2019 | Non-covered Recipient Entity PMG Research of Raleigh LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671672515 |
| Principal investigator 1 | Allergan Inc. | $9,861.00 | 08/16/2019 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670066884 |
| Principal investigator 1 | PFIZER INC. | $2,334.15 | 08/14/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671678697 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2,440.00 | 08/12/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691449665 |
| Principal investigator 1 | Novo Nordisk AS | $97.20 | 08/07/2019 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4375 | No dispute reported | 06/30/2026 | 706703599 |
| Principal investigator 1 | PFIZER INC. | $13,152.05 | 08/06/2019 | Non-covered Recipient Entity PMG Research of Raleigh LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671678973 |
| Principal investigator 1 | Novo Nordisk AS | $10,179.24 | 07/30/2019 | Non-covered Recipient Entity PMG RESEARCH INC | NN9536-4375 | No dispute reported | 06/30/2026 | 692453775 |
| Principal investigator 1 | Novo Nordisk AS | $114.51 | 07/30/2019 | Non-covered Recipient Entity PMG RESEARCH INC | NN9536-4375 | No dispute reported | 06/30/2026 | 692453777 |
| Principal investigator 1 | PFIZER INC. | $65.00 | 07/24/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671655573 |
| Principal investigator 1 | PFIZER INC. | $50.00 | 07/24/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671655575 |
| Principal investigator 1 | PFIZER INC. | $743.85 | 07/24/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671656849 |
| Principal investigator 1 | PFIZER INC. | $375.00 | 07/24/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671657429 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $1,774.80 | 07/18/2019 | Non-covered Recipient Entity PMG RESEARCH INC | K-877-302 | No dispute reported | 06/30/2026 | 629130009 |
| Principal investigator 1 | PFIZER INC. | $3,712.83 | 07/18/2019 | Non-covered Recipient Entity PMG Research of Raleigh LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671671661 |
| Principal investigator 1 | PFIZER INC. | $240.47 | 07/17/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671656653 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,797.00 | 07/10/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691449655 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $3,000.00 | 07/10/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691449667 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $9,174.00 | 07/10/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691451475 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $0.38 | 07/10/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691451583 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $0.68 | 07/10/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691451589 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $20.00 | 07/10/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691451593 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2.75 | 07/10/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691453555 |
| Principal investigator 1 | PFIZER INC. | $17,219.37 | 07/10/2019 | Non-covered Recipient Entity PMG Research of Raleigh LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671671981 |
| Principal investigator 1 | PFIZER INC. | $1,830.77 | 07/02/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671657911 |
| Principal investigator 1 | Allergan Inc. | $7,000.00 | 07/01/2019 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 670054315 |
| Principal investigator 1 | Allergan Inc. | $1,000.00 | 07/01/2019 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 670054317 |
| Principal investigator 1 | PFIZER INC. | $1,372.27 | 06/26/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671657821 |
| Principal investigator 1 | Novo Nordisk AS | $6,213.05 | 06/25/2019 | Non-covered Recipient Entity PMG RESEARCH INC | NN9536-4375 | No dispute reported | 06/30/2026 | 692453769 |
| Principal investigator 1 | PFIZER INC. | $17,313.76 | 06/22/2019 | Non-covered Recipient Entity PMG Research of Raleigh LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671653803 |
| Principal investigator 1 | Novo Nordisk AS | $200.40 | 06/20/2019 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4375 | No dispute reported | 06/30/2026 | 706703535 |
| Principal investigator 1 | Allergan Inc. | $1,040.00 | 06/18/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670051757 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $12.10 | 06/10/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691389577 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1.20 | 06/10/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691390018 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $4.04 | 06/10/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691390043 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $4.84 | 06/10/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691390047 |
| Principal investigator 1 | PFIZER INC. | $628.42 | 06/01/2019 | Non-covered Recipient Entity PMG Research of Raleigh | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 671656503 |
| Principal investigator 1 | PFIZER INC. | $1,885.26 | 05/29/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671654775 |
| Principal investigator 1 | Novo Nordisk AS | $9,325.20 | 05/28/2019 | Non-covered Recipient Entity PMG RESEARCH INC | NN9536-4375 | No dispute reported | 06/30/2026 | 692453767 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $2,889.90 | 05/22/2019 | Non-covered Recipient Entity PMG RESEARCH INC | K-877-302 | No dispute reported | 06/30/2026 | 629129989 |
| Principal investigator 1 | PFIZER INC. | $628.42 | 05/22/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671654851 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $14.69 | 05/22/2019 | Non-covered Recipient Individual | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 685027899 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $15.00 | 05/22/2019 | Non-covered Recipient Individual | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 685027905 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $45.13 | 05/22/2019 | Non-covered Recipient Individual | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 685027915 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $66.00 | 05/22/2019 | Non-covered Recipient Individual | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 685027921 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2,739.00 | 05/20/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691317005 |
| Principal investigator 1 | Novo Nordisk AS | $80.04 | 05/20/2019 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4375 | No dispute reported | 06/30/2026 | 706703427 |
| Principal investigator 1 | Novo Nordisk AS | $80.04 | 05/20/2019 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4375 | No dispute reported | 06/30/2026 | 706703429 |
| Principal investigator 1 | PFIZER INC. | $2,069.55 | 05/18/2019 | Non-covered Recipient Entity PMG Research of Raleigh | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 671658135 |
| Principal investigator 1 | PFIZER INC. | $1,962.22 | 05/15/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671654809 |
| Principal investigator 1 | PFIZER INC. | $7,351.35 | 05/10/2019 | Non-covered Recipient Entity PMG Research of Raleigh | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 671654441 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $263.56 | 05/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691389453 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $175.80 | 05/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691389587 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $19.00 | 05/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691389963 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $6.80 | 05/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691390051 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $7.60 | 05/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691396739 |
| Principal investigator 1 | PFIZER INC. | $1,256.84 | 05/08/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671654363 |
| Principal investigator 1 | PFIZER INC. | $6,200.00 | 05/08/2019 | Non-covered Recipient Entity PMG Research of Raleigh LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671654777 |
| Principal investigator 1 | Allergan Inc. | $1,004.00 | 05/07/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 670043861 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $7,822.80 | 05/06/2019 | Non-covered Recipient Entity PMG RESEARCH INC | K-877-302 | No dispute reported | 06/30/2026 | 629129991 |
| Principal investigator 1 | PFIZER INC. | $375.00 | 05/01/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671654419 |
| Principal investigator 1 | PFIZER INC. | $3,821.87 | 05/01/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671654811 |
| Principal investigator 1 | PFIZER INC. | $65.00 | 05/01/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671654813 |
| Principal investigator 1 | PFIZER INC. | $506.25 | 05/01/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671654853 |
| Principal investigator 1 | PFIZER INC. | $100.00 | 05/01/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671654855 |
| Principal investigator 1 | Novo Nordisk AS | $10,223.32 | 04/25/2019 | Non-covered Recipient Entity PMG RESEARCH INC | NN9536-4375 | No dispute reported | 06/30/2026 | 692453763 |
| Principal investigator 1 | Novo Nordisk AS | $187.50 | 04/25/2019 | Non-covered Recipient Entity PMG RESEARCH INC | NN9536-4375 | No dispute reported | 06/30/2026 | 692453765 |
| Principal investigator 1 | PFIZER INC. | $10,683.14 | 04/23/2019 | Non-covered Recipient Entity PMG Research of Raleigh | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 671654439 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $3,872.00 | 04/12/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691318281 |
| Principal investigator 1 | PFIZER INC. | $9,695.74 | 04/10/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671654361 |
| Principal investigator 1 | PFIZER INC. | $1,256.84 | 04/09/2019 | Non-covered Recipient Entity PMG Research of Raleigh | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 671654437 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $20.40 | 04/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691389443 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $242.00 | 04/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691389447 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $3.90 | 04/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691389457 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $148.50 | 04/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691389581 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $35.20 | 04/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691389833 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $82.50 | 04/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691389903 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $10.65 | 04/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691390021 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $198.00 | 04/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691390025 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2.10 | 04/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691390029 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $60.50 | 04/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691390053 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $792.00 | 04/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691390057 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $100.80 | 04/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691390089 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $11.40 | 04/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691390093 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $9.90 | 04/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691391835 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $99.00 | 04/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691391837 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $99.00 | 04/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691391841 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $28.50 | 04/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691396313 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2.00 | 04/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691396345 |
| Principal investigator 1 | PFIZER INC. | $4,415.03 | 03/27/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671654359 |
| Principal investigator 1 | Novo Nordisk AS | $18,627.88 | 03/26/2019 | Non-covered Recipient Entity PMG RESEARCH INC | NN9536-4375 | No dispute reported | 06/30/2026 | 692453761 |
| Principal investigator 1 | PFIZER INC. | $6,347.37 | 03/26/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 671654381 |
| Principal investigator 1 | PFIZER INC. | $8,769.13 | 03/20/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671654773 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2,172.00 | 03/13/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691317789 |
| Principal investigator 1 | PFIZER INC. | $1,256.84 | 03/13/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671654871 |
| Principal investigator 1 | PFIZER INC. | $2,849.55 | 03/05/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 671654379 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2,964.00 | 03/04/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691326441 |
| Principal investigator 1 | Novo Nordisk AS | $20,486.39 | 02/26/2019 | Non-covered Recipient Entity PMG RESEARCH INC | NN9536-4375 | No dispute reported | 06/30/2026 | 692453759 |
| Principal investigator 1 | Amarin Pharma Inc. | $5,285.50 | 02/21/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the effect of AMR101 on Cardiovascular Heath and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardio | No dispute reported | 06/30/2026 | 700952273 |
| Principal investigator 1 | PFIZER INC. | $1,256.84 | 02/20/2019 | Non-covered Recipient Entity PMG Research of Raleigh | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 671654383 |
| Principal investigator 1 | PFIZER INC. | $3,472.37 | 02/20/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671655047 |
| Principal investigator 1 | PFIZER INC. | $5,162.07 | 02/13/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671654801 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $693.00 | 02/07/2019 | Non-covered Recipient Entity PMG RESEARCH INC | K-877-302 | No dispute reported | 06/30/2026 | 629129967 |
| Principal investigator 1 | Novo Nordisk AS | $160.68 | 02/07/2019 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4375 | No dispute reported | 06/30/2026 | 706703287 |
| Principal investigator 1 | PFIZER INC. | $5,310.37 | 02/05/2019 | Non-covered Recipient Entity PMG Research of Raleigh | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 671657933 |
| Principal investigator 1 | PFIZER INC. | $3,459.53 | 02/04/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671655143 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,053.17 | 01/28/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691396278 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,264.00 | 01/25/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691308773 |
| Principal investigator 1 | Novo Nordisk AS | $275.00 | 01/24/2019 | Non-covered Recipient Entity PMG RESEARCH INC | NN9536-4375 | No dispute reported | 06/30/2026 | 692453755 |
| Principal investigator 1 | Novo Nordisk AS | $28,628.82 | 01/24/2019 | Non-covered Recipient Entity PMG RESEARCH INC | NN9536-4375 | No dispute reported | 06/30/2026 | 692453757 |
| Principal investigator 1 | PFIZER INC. | $15,082.08 | 01/23/2019 | Non-covered Recipient Entity PMG Research of Raleigh | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 671654841 |
| Principal investigator 1 | Kowa Research Institute, Inc. | $1,386.00 | 01/21/2019 | Non-covered Recipient Entity PMG RESEARCH INC | K-877-302 | No dispute reported | 06/30/2026 | 629129969 |
| Principal investigator 1 | PFIZER INC. | $13,741.99 | 01/16/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671654991 |
| Principal investigator 1 | PFIZER INC. | $13,652.48 | 01/16/2019 | Non-covered Recipient Entity PMG Research of Raleigh | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 671658155 |
| Principal investigator 1 | PFIZER INC. | $65.00 | 01/09/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671654761 |
| Principal investigator 1 | PFIZER INC. | $375.00 | 01/09/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671655145 |
| Principal investigator 1 | PFIZER INC. | $2,900.00 | 01/09/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671655183 |
| Principal investigator 1 | PFIZER INC. | $100.00 | 01/09/2019 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671658101 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $5,136.00 | 01/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691310701 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2,917.29 | 01/08/2019 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH, LLC | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 691311007 |